Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome

Canine Cushing's syndrome (hypercortisolism) can be caused by a pituitary tumor (pituitary-dependent hypercortisolism; PDH) or a cortisol-secreting adrenocortical tumor (csACT). For both cases, non-invasive biomarkers that could pre-operatively predict the risk of recurrence after surgery would...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Karin Sanders, Anouk Veldhuizen, Hans S. Kooistra, Adri Slob, Elpetra P. M. Timmermans-Sprang, Frank M. Riemers, Sylvie Daminet, Federico Fracassi, Sebastiaan A. van Nimwegen, Björn P. Meij, Sara Galac
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/269ddf2aae4b4e2c8678a767f0a369a1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:269ddf2aae4b4e2c8678a767f0a369a1
record_format dspace
spelling oai:doaj.org-article:269ddf2aae4b4e2c8678a767f0a369a12021-11-17T04:58:04ZCirculating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome2297-176910.3389/fvets.2021.760487https://doaj.org/article/269ddf2aae4b4e2c8678a767f0a369a12021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fvets.2021.760487/fullhttps://doaj.org/toc/2297-1769Canine Cushing's syndrome (hypercortisolism) can be caused by a pituitary tumor (pituitary-dependent hypercortisolism; PDH) or a cortisol-secreting adrenocortical tumor (csACT). For both cases, non-invasive biomarkers that could pre-operatively predict the risk of recurrence after surgery would greatly impact clinical decision making. The aim of this study was to determine whether circulating microRNAs (miRNAs) can be used as diagnostic (presence of PDH or csACT) and/or prognostic (disease recurrence, histological grade) non-invasive biomarkers for canine Cushing's syndrome. After a pilot study with 40 miRNAs in blood samples of healthy dogs (n = 3), dogs with PDH (n = 3) and dogs with a csACT (n = 4), we selected a total of 20 miRNAs for the definitive study. In the definitive study, these 20 miRNAs were analyzed in blood samples of healthy dogs (n = 6), dogs with PDH (n = 19, pre- and post-operative samples) and dogs with a csACT (n = 26, pre-operative samples). In dogs with PDH, six miRNAs (miR-122-5p, miR-126-5p, miR-141-3p, miR-222-3p, miR-375-3p and miR-483-3p) were differentially expressed compared to healthy dogs. Of one miRNA, miR-122-5p, the expression levels did not overlap between healthy dogs and dogs with PDH (p = 2.9x10−4), significantly decreased after hypophysectomy (p = 0.013), and were significantly higher (p = 0.017) in dogs with recurrence (n = 3) than in dogs without recurrence for at least one year after hypophysectomy (n = 7). In dogs with csACTs, two miRNAs (miR-483-3p and miR-223-3p) were differentially expressed compared to healthy dogs. Additionally, miR-141-3p was expressed significantly lower (p = 0.009) in dogs with csACTs that had a histopathological Utrecht score of ≥ 11 compared to those with a score of <11. These results indicate that circulating miRNAs have the potential to be non-invasive biomarkers in dogs with Cushing's syndrome that may contribute to clinical decision making.Karin SandersAnouk VeldhuizenHans S. KooistraAdri SlobElpetra P. M. Timmermans-SprangFrank M. RiemersSylvie DaminetFederico FracassiSebastiaan A. van NimwegenBjörn P. MeijSara GalacFrontiers Media S.A.articlemiRNApituitary-dependent hypercortisolismCushing's diseaseadrenocortical tumormiR-122prognosticVeterinary medicineSF600-1100ENFrontiers in Veterinary Science, Vol 8 (2021)
institution DOAJ
collection DOAJ
language EN
topic miRNA
pituitary-dependent hypercortisolism
Cushing's disease
adrenocortical tumor
miR-122
prognostic
Veterinary medicine
SF600-1100
spellingShingle miRNA
pituitary-dependent hypercortisolism
Cushing's disease
adrenocortical tumor
miR-122
prognostic
Veterinary medicine
SF600-1100
Karin Sanders
Anouk Veldhuizen
Hans S. Kooistra
Adri Slob
Elpetra P. M. Timmermans-Sprang
Frank M. Riemers
Sylvie Daminet
Federico Fracassi
Sebastiaan A. van Nimwegen
Björn P. Meij
Sara Galac
Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome
description Canine Cushing's syndrome (hypercortisolism) can be caused by a pituitary tumor (pituitary-dependent hypercortisolism; PDH) or a cortisol-secreting adrenocortical tumor (csACT). For both cases, non-invasive biomarkers that could pre-operatively predict the risk of recurrence after surgery would greatly impact clinical decision making. The aim of this study was to determine whether circulating microRNAs (miRNAs) can be used as diagnostic (presence of PDH or csACT) and/or prognostic (disease recurrence, histological grade) non-invasive biomarkers for canine Cushing's syndrome. After a pilot study with 40 miRNAs in blood samples of healthy dogs (n = 3), dogs with PDH (n = 3) and dogs with a csACT (n = 4), we selected a total of 20 miRNAs for the definitive study. In the definitive study, these 20 miRNAs were analyzed in blood samples of healthy dogs (n = 6), dogs with PDH (n = 19, pre- and post-operative samples) and dogs with a csACT (n = 26, pre-operative samples). In dogs with PDH, six miRNAs (miR-122-5p, miR-126-5p, miR-141-3p, miR-222-3p, miR-375-3p and miR-483-3p) were differentially expressed compared to healthy dogs. Of one miRNA, miR-122-5p, the expression levels did not overlap between healthy dogs and dogs with PDH (p = 2.9x10−4), significantly decreased after hypophysectomy (p = 0.013), and were significantly higher (p = 0.017) in dogs with recurrence (n = 3) than in dogs without recurrence for at least one year after hypophysectomy (n = 7). In dogs with csACTs, two miRNAs (miR-483-3p and miR-223-3p) were differentially expressed compared to healthy dogs. Additionally, miR-141-3p was expressed significantly lower (p = 0.009) in dogs with csACTs that had a histopathological Utrecht score of ≥ 11 compared to those with a score of <11. These results indicate that circulating miRNAs have the potential to be non-invasive biomarkers in dogs with Cushing's syndrome that may contribute to clinical decision making.
format article
author Karin Sanders
Anouk Veldhuizen
Hans S. Kooistra
Adri Slob
Elpetra P. M. Timmermans-Sprang
Frank M. Riemers
Sylvie Daminet
Federico Fracassi
Sebastiaan A. van Nimwegen
Björn P. Meij
Sara Galac
author_facet Karin Sanders
Anouk Veldhuizen
Hans S. Kooistra
Adri Slob
Elpetra P. M. Timmermans-Sprang
Frank M. Riemers
Sylvie Daminet
Federico Fracassi
Sebastiaan A. van Nimwegen
Björn P. Meij
Sara Galac
author_sort Karin Sanders
title Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome
title_short Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome
title_full Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome
title_fullStr Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome
title_full_unstemmed Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome
title_sort circulating micrornas as non-invasive biomarkers for canine cushing's syndrome
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/269ddf2aae4b4e2c8678a767f0a369a1
work_keys_str_mv AT karinsanders circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT anoukveldhuizen circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT hansskooistra circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT adrislob circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT elpetrapmtimmermanssprang circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT frankmriemers circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT sylviedaminet circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT federicofracassi circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT sebastiaanavannimwegen circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT bjornpmeij circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
AT saragalac circulatingmicrornasasnoninvasivebiomarkersforcaninecushingssyndrome
_version_ 1718425913575604224